Cargando…
Exacerbation of psoriasis induced by Nivolumab in a patient with stage IIIc gastric adenocarcinoma: A case report and literature review
Nivolumab, the programmed cell death 1 inhibitor, is a kind of immune checkpoint inhibitor commonly used to treat advanced cancers. Unfortunately, such drugs often induce various immune-related adverse events involving different body systems, with psoriasis being one of the skin toxicities. We repor...
Autores principales: | Sun, Xiaojie, Mei, Xiaole, Liu, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958049/ https://www.ncbi.nlm.nih.gov/pubmed/36852017 http://dx.doi.org/10.1016/j.jtauto.2023.100193 |
Ejemplares similares
-
Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020) -
D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
por: Peng, Jin, et al.
Publicado: (2016) -
3D printing lunate prosthesis for stage IIIc Kienböck’s disease: a case report
por: Xie, Mei-ming, et al.
Publicado: (2017) -
Nivolumab/tozinameran: Flare-up of psoriasis: case report
Publicado: (2021) -
Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma
por: Glinos, George D., et al.
Publicado: (2021)